BCLSI
CBAY

Bain Capital Life Sciences Investors’s Cymabay Therapeutics CBAY Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-913,969
Closed -$13.6M – 32
2023
Q3 		$13.6M Sell
913,969
-1,586,031
-63% -$21M 1.52% 16
2023
Q2 		$27.4M Hold
2,500,000
– – 2.82% 14
2023
Q1 		$21.8M Buy
+2,500,000
New +$20M 2.72% 13

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bain Capital Life Sciences Investors's CBAY Position: Q4 2023 in Review

Bain Capital Life Sciences Investors sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 913,969 shares — an estimated $13.6M sold.

Bain Capital Life Sciences Investors first reported a position in CBAY in Q1 2023 and held it in 3 quarters. The position peaked at $27.4M in Q2 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

  • Bain Capital Life Sciences Investors reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 913,969 Cymabay Therapeutics shares in Q4 2023, an estimated $13.6M.
  • Bain Capital Life Sciences Investors first reported a position in Cymabay Therapeutics in Q1 2023 and held it in 3 quarters.
  • Bain Capital Life Sciences Investors's Cymabay Therapeutics position peaked at $27.4M in Q2 2023.
  • 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2023, filed 13 Feb 2024.